Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

被引:36
作者
Ikeda, Satoshi [1 ]
Arita, Machiko [1 ]
Misaki, Kenta [2 ]
Mishima, Shohei [1 ]
Takaiwa, Takuya [1 ]
Nishiyama, Akihiro [1 ]
Ito, Akihiro [1 ]
Furuta, Kenjiro [1 ]
Yokoyama, Toshihide [1 ]
Tokioka, Fumiaki [1 ]
Noyama, Maki [1 ]
Yoshioka, Hiroshige [1 ]
Ishida, Tadashi [1 ]
机构
[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama 7108602, Japan
[2] Kurashiki Cent Hosp, Dept Rheumatol, Kurashiki, Okayama 7108602, Japan
来源
SPRINGERPLUS | 2015年 / 4卷
关键词
Interstitial lung disease; Malignancy; Polymyositis; Dermatomyositis; Clinically amyopathic dermatomyositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; POPULATION-BASED COHORT; SINE MYOSITIS; CANCER; RISK; AUTOANTIBODIES; PNEUMONITIS; SPECTRUM; LINK;
D O I
10.1186/s40064-015-1013-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM, and CADM. We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and Peter's criteria (PM/DM) and Sontheimer's criteria and Gerami's criteria (CADM), focusing on ILD and malignancy. ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM. Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127-0.372; p = 0.00190] and significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17-23.1; p = 0.0299) than in other patients. Patients with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from refractory ILD = 90 days from the first visit; neither death nor recurrence occurred subsequently. In conclusion, a positive association between DM and malignancy and a negative association between ILD and malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence occurred subsequently.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Interstitial lung disease in polymyositis and dermatomyositis.
    Schnabel A.
    Hellmich B.
    Gross W.L.
    Current Rheumatology Reports, 2005, 7 (2) : 99 - 105
  • [32] Interstitial lung disease in polymyositis and dermatomyositis
    Fathi, M
    Lundberg, IE
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 701 - 706
  • [33] Idiopathic Inflammatory Myopathy Associated with Malignancy: A Retrospective Cohort of 151 Korean Patients with Dermatomyositis and Polymyositis
    So, Min Wook
    Koo, Bon San
    Kim, Yong-Gil
    Lee, Chang-Keun
    Yoo, Bin
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (11) : 2432 - 2435
  • [34] The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study
    Lim, Chong Hong
    Tseng, Chih-Wei
    Lin, Ching-Tsai
    Huang, Wen-Nan
    Chen, Yi-Hsing
    Chen, Yi-Ming
    Chen, Der-Yuan
    SAGE OPEN MEDICINE, 2018, 6
  • [35] Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020
    Sun, Kun-Yan
    Fan, Yong
    Wang, Yun-Xia
    Zhong, Yi-Jue
    Wang, Guang-Fa
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2021, 51 (01) : 175 - 191
  • [36] Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease
    Li, Liubing
    Wang, Han
    Wang, Qian
    Wu, Chanyuan
    Liu, Chenxi
    Zhang, Yanfang
    Cheng, Linlin
    Zeng, Xiaofeng
    Zhang, Fengchun
    Li, Yongzhe
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 397 : 123 - 128
  • [37] The Prevalence of Dementia among Dermatomyositis and Polymyositis Patients: A Retrospective Cohort Study
    Patt, Yonatan Shneor
    Ben-Shabat, Niv
    Fisher, Lior
    Amital, Howard
    Watad, Abdulla
    Sharif, Kassem
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2023, 25 (07): : 479 - 484
  • [38] Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
    Sun, Yuechi
    He, Yan
    Liu, Yuan
    Shi, Guixiu
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (06) : 521 - 524
  • [39] Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease
    Nakatsuka, Yoshinari
    Handa, Tomohiro
    Nakashima, Ran
    Tanizawa, Kiminobu
    Kubo, Takeshi
    Murase, Yuko
    Sokai, Akihiko
    Ikezoe, Kohei
    Hosono, Yuji
    Watanabe, Kizuku
    Tokuda, Shinsaku
    Uno, Kazuko
    Yoshizawa, Akihiko
    Tsuruyama, Tatsuaki
    Uozumi, Ryuji
    Nagai, Sonoko
    Hatta, Kazuhiro
    Taguchi, Yoshio
    Mishima, Michiaki
    Chin, Kazuo
    Mimori, Tsuneyo
    Hirai, Toyohiro
    RHEUMATOLOGY, 2019, 58 (08) : 1465 - 1473
  • [40] Clinically Amyopathic Dermatomyositis With Rapid Progressive Interstitial Lung Disease Diagnosed in a Patient on Extracorporeal Membrane Oxygenation
    Al-Husayni, Faisal
    Munshi, Adeeb
    Qanash, Sultan
    Shaikhain, Talal A.
    Alzahrani, Zeyad
    Alghamdi, Bader
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)